Healthcare Industry News: Terumo
News Release - January 28, 2008
Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel TechnologySOMERSET, N.J., Jan. 28 (HSMN NewsFeed) -- The newest product offered by Terumo is literally expanding the company's interventional device portfolio.
Terumo Interventional Systems announces the launch of the AZUR Peripheral HydroCoil Embolization System for the occlusion of blood vessels, vascular malformations, and aneurysms. AZUR is the only peripheral platinum coil embolization system with a hydrogel coating that expands when introduced into the bloodstream, delivering greater filling and mechanical occlusion - all with fewer coils.
AZUR's hydrogel coating undergoes limited expansion within the first 3 minutes, and fully expands within 20 minutes. The result is greater filling and mechanical stability with fewer coils - nearly 5 times more filling volume for the 0.018" coil and 4 times more filling volume for the 0.035" coil (versus platinum coils of the same size).
In addition to its unique HydroCoil technology, AZUR is the only peripheral embolization system to offer a truly detachable system, giving physicians the ability to detach coils in less than a second and at the push of a button. With the capability to withdraw and reposition the coil until the coil is securely placed, the system minimizes the risk of non-target embolization and coil migration. This offers a whole new level of control, making it ideal for high-flow areas and challenging vascular anatomy.
Dr. Craig Greben, Chief of the Division of Interventional Radiology at the North Shore University Hospital on Long Island in New York, was the first physician to successfully use the AZUR Peripheral HydroCoil Embolization System in his practice. Deploying AZUR in a patient who had 2 large splenic artery aneurysms, Dr. Greben reported that AZUR filled the aneurysm with precision and ease and required fewer coils.
"We believe that AZUR enables interventionalists to approach even the most challenging anatomy with new capability and confidence," says Fernando Yuste, Marketing Manager of Interventional Products for Terumo Interventional Systems. "With the initial feedback that we've received from physicians, we're predicting that AZUR will be the new gold standard for endovascular occlusion of vascular lesions."
For more information, customers can contact Terumo Interventional Systems by calling its Inside Sales Customer Care Team at 800-862-4143 or by visiting http://www.Terumois.com .
Terumo Interventional Systems
Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.
Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists and Vascular Surgeons are among the medical professionals who depend upon TIS products to access and cross difficult-to- reach lesions thereby allowing therapeutic intervention in previously unreachable vascular beds.
Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $2.3 billion in sales and operations in more than 150 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:JP) and is a component of the Nikkei 225, Japan's leading stock index.
Source: Terumo Interventional Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.